We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

134 hedge funds and large institutions have $847M invested in Verve Therapeutics in 2023 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 24

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

40% more call options, than puts

Call options by funds: $7M | Put options by funds: $4.99M

11% more funds holding

Funds holding: 121 → 134 (+13)

0.31% more ownership

Funds ownership: 99.94% → 100.25% (+0.31%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

27% less capital invested

Capital invested by funds: $1.16B → $847M (-$313M)

Holders
134
Holders Change
+13
Holders Change %
+10.74%
% of All Funds
2.13%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
27
Increased
58
Reduced
24
Closed
14
Calls
$7M
Puts
$4.99M
Net Calls
+$2M
Net Calls Change
+$1.64M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$11.9M
2
JP Morgan Chase
JP Morgan Chase
New York
+$10.7M
3
CC
Casdin Capital
New York
+$9.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.55M
5
LGM
Logos Global Management
California
+$3.46M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$9.55M
2
NHAS
Novo Holdings A/S
Denmark
-$9.38M
3
Citadel Advisors
Citadel Advisors
Florida
-$7.39M
4
RG
Redmile Group
California
-$4.06M
5
PHS
PFM Health Sciences
California
-$3.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
26
Artal Group
Luxembourg
$3.98M – – –
Morgan Stanley
27
Morgan Stanley
New York
$3.93M -$738K -45,826 -13%
APM
28
Avidity Partners Management
Texas
$3.78M -$9.55M -593,266 -68%
GW
29
GW & Wade
Massachusetts
$3.44M – – –
Citadel Advisors
30
Citadel Advisors
Florida
$3.15M -$7.39M -458,837 -66%
ECM
31
ExodusPoint Capital Management
New York
$3.08M +$685K +42,549 +22%
LGM
32
Logos Global Management
California
$2.85M +$3.46M +215,000 New
Mirae Asset Global Investments
33
Mirae Asset Global Investments
South Korea
$2.81M +$278K +17,277 +9%
FCM
34
Farallon Capital Management
California
$2.8M +$3.4M +211,293 New
Goldman Sachs
35
Goldman Sachs
New York
$2.73M -$991K -61,541 -23%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$2.48M +$6.55K +407 +0.2%
N
37
Nuveen
North Carolina
$2.37M +$44.1K +2,740 +2%
Barclays
38
Barclays
United Kingdom
$1.91M +$369K +22,898 +19%
Citigroup
39
Citigroup
New York
$1.6M +$501K +31,126 +35%
CSS
40
Cubist Systematic Strategies
Connecticut
$1.55M +$1.26M +78,141 +203%
Swiss National Bank
41
Swiss National Bank
Switzerland
$1.26M +$124K +7,700 +9%
Millennium Management
42
Millennium Management
New York
$1.22M +$1.48M +91,948 New
UBS Group
43
UBS Group
Switzerland
$1.1M -$77.5K -4,811 -5%
VIG
44
Vienna Insurance Group
Poland
$1.06M +$1.29M +80,000 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$1.06M +$3.53K +219 +0.3%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$1.04M +$1.17M +72,528 New
SC
47
Saltoro Capital
Texas
$882K +$1.07M +66,500 New
Wells Fargo
48
Wells Fargo
California
$846K +$53.4K +3,314 +5%
Ameriprise
49
Ameriprise
Minnesota
$823K +$226K +14,008 +29%
GCP
50
GSA Capital Partners
United Kingdom
$754K +$916K +56,895 New
1
2
3 4 5

VERV Hedge Fund Activity: Q3 2023 in Review

134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2023, worth a combined $847M — down 27% from $1.16B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new VERV positions and 14 closed out — a net gain of 13 holders — while 58 added to existing stakes and 24 trimmed.

The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was Avidity Partners Management, cutting an estimated $9.55M.

  • 134 institutional investors held Verve Therapeutics (VERV) as of Q3 2023, up from 121 in Q2 2023.
  • Funds reported $847M of Verve Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
  • 27 funds opened new Verve Therapeutics positions in Q3 2023 and 14 closed out, a net change of +13 holders.
  • The largest Verve Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $11.9M added.
  • The largest Verve Therapeutics seller in Q3 2023 was Avidity Partners Management, an estimated $9.55M sold.

Based on aggregated 13F filings for Q3 2023.